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Background: Several peptides, named adipokines, are produced by the adipose tissue. Among those, adiponectin
(AD) is the most abundant. AD promotes peripheral insulin sensitivity, inhibits liver gluconeogenesis and displays
anti-atherogenic and anti-inflammatory properties. Lower levels of AD are related to a higher risk of myocardial
infarction and a worse prognosis in patients with coronary artery disease. However, despite a favorable clinical
profile, AD increases in relation to worsening heart failure (HF); in this context, higher adiponectinemia is reliably
related to poor prognosis. There is still little knowledge about how certain metabolic conditions, such as diabetes
mellitus, modulate the relationship between AD and HF.
We evaluated the level of adiponectin in patients with ischemic HF, with and without type 2 diabetes, to elucidate
whether the metabolic syndrome was able to influence the relationship between AD and HF.
Results: We demonstrated that AD rises in patients with advanced HF, but to a lesser extent in diabetics than in
non-diabetics. Diabetic patients with reduced systolic performance orchestrated a slower rise of AD which began
only in face of overt HF. The different behavior of AD in the presence of diabetes was not entirely explained by
differences in body mass index. In addition, NT-proBNP, the second strongest predictor of AD, did not differ
significantly between diabetic and non-diabetic patients. These data indicate that some other mechanisms are
involved in the regulation of AD in patients with type 2 diabetes and coronary artery disease.
Conclusions: AD rises across chronic heart failure stages but this phenomenon is less evident in type 2 diabetic
patients. In the presence of diabetes, the progressive increase of AD in relation to the severity of LV dysfunction is
hampered and becomes evident only in overt HF.
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The adipose tissue should not be regarded as a simple
site of lipid storage [1]; indeed it is able to secrete sev-
eral peptides with hormonal properties that are involved
in energy homeostasis as well as modulation of inflam-
mation and regulation of many immunological mechan-
isms [2]. This heterogeneous group of hormones is
named adipokines. Among these, adiponectin (AD) is by
far the most abundant protein secreted by the adipose* Correspondence: pesine@libero.it
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distribution, and reproduction in any mediumtissue [3]. Although it is produced almost exclusively by
adipocytes, plasma levels of AD are found to be inversely
correlated to visceral adiposity and body mass index
(BMI) [3]. AD promotes peripheral insulin sensitivity [4]
and inhibition of liver gluconeogenesis [5]. As a matter
of fact, hypoadiponectinemia is known to be the molecu-
lar link between obesity and insulin-resistance, at the
base of metabolic syndrome [2]. AD is able to predict
diabetes onset and diabetic patients always show lower
plasma levels of AD compared to the general population
[6]. In addition, it has been reported that plasma level of
adiponectin in diabetic subjects with foot ulceration was
lower than in diabetic subjects without diabetic foot [7],ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the microvascular complications of diabetes.
Beside of its beneficial role in the glycometabolic path-
way, AD shows several favorable properties as an anti-
atherogenic and anti-inflammatory agent [8]. Several stud-
ies report an AD mediated inhibition of many peptides
and cytokines involved in the progression of atheroscler-
osis [9]. At the same time, AD seems to counteract the
transition from stable atheromatic plaques to vulnerable
ones [10]. Given these properties, it is not unexpected that
hypoadiponectinemia is related to coronary artery disease
(CAD) [11]. In fact plasma, levels of AD are able to pre-
dict not only the risk of myocardial infarction but also the
prognosis and clinical course of CAD [10].
Because of all the beneficial effects on insulin resistance
and atherosclerosis, it came as a surprise the observation
that plasma levels of AD were elevated in chronic heart
failure (HF) [12]. In fact, AD seems to increase in relation
to worsening HF [13] and it is reliably related to poor
prognosis [14]. Three main hypotheses have been pro-
posed to explain this apparent paradox. The first one sug-
gests that cachexia related to HF is responsible for the
upsurge of AD [15]. A second hypothesis relates to the
possibility of an adiponectin resistance: indeed, a lower
density of AD receptors has been detected on musculo-
skeletal cells from HF patients [16]. The last suggestion
came from an elegant study by Tsukamoto and coll. that
showed how NT-proBNP is able to induce AD secretion
from adipocytes. Furthermore, they found that injection of
NT-proBNP in humans caused an increase in AD when
compared to saline solution [17]. Based on an overall ana-
lysis of all data available, Park and coll. recently speculated
that although high adiponectin levels may confer cardio-
protection in the acute setting, i.e. during acute myocar-
dial infarction, it may contribute in a permissive way to
adverse remodeling in the post-acute period, accelerating
the transition to heart failure [18].
Several factors are known to predict adiponectinemia;
among those NT-proBNP and BMI are the most rele-
vant [19]. However, little or nothing is known about howFigure 1 Flow chart of the study.certain metabolic conditions, such as diabetes mellitus
(DM), modulate the correlation between AD and HF.
Our aims were i) to evaluate plasma levels of AD in
patients affected by ischemic HF with and without type
2 DM, ii) to analyze the correlation between adiponecti-
nemia and ACC/AHA stage of chronic HF, and iii) to
elucidate whether the presence of DM was able to
influence the relationship between HF and AD levels.
Methods
Study subjects
We enrolled 150 consecutive outpatients referred to the
Geriatric Cardiology and Medicine Unit of Careggi Aca-
demic Hospital (Florence, Italy) for CAD between Janu-
ary 1st, 2008 and December 31st, 2010. All patients were
Caucasians and met the following inclusion criteria:
written informed consent, CAD documented by at least
one ≥ 75% stenosis of a major epicardial branch at cor-
onary angiography, no hospitalization for worsening HF
during the last two months. Those with type 2 diabetes
were classified according to ADA criteria [20]. The study
was approved by an institutional review committee.
Clinical and instrumental data
We collected a thorough clinical history, including symp-
toms needed to define New York Heart Association
(NYHA) class. Patients underwent physical examination
with measurement of height and weight to calculate BMI,
12-lead electrocardiogram, and 6-min walking test
(6MWT) [21]. A standard echocardiographic study was
carried out following the American Society of Echocardi-
ography recommendations [22] using a 4-chamber apical
view to calculate left ventricular ejection fraction (LVEF),
according to the Simpson’s formula. Heart failure was
considered to be overt in the presence of positive Euro-
pean Society of Cardiology criteria [23], coupled with a
Boston score ≥5 [24]. As reported in the flow chart of
Figure 1, the study population was divided into two groups:
the diabetes (D) group which included patients with
diagnosis of type 2 DM, and the non-diabetes (ND) group.
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according to ACC/AHA guidelines for chronic HF [25]
each group was further divided into three subgroups as
follows: group A including patients with LVEF ≥55%,
no overt HF; group B, LVEF <40%, no overt HF and
group C, LVEF <40%, overt HF. Patients with LVEF in
the 40-54% range were excluded from the study in order
to select subjects with markedly different LV systolic
function. Subgroups were marked as follows: AND, BND
and CND, including patients without diabetes, and AD,
BD and CD which comprised patients with type 2 DM
(Figure 1).
The level of non-cardiac comorbidity was measured
with the Greenfield’s Index of Disease Severity (IDS)
score [26], whereas the presence of depressive symptoms
was evaluated with the 30-item form of the Geriatric
Depression Scale (GDS) [27].
Biochemical data
Venous blood samples were drawn in the fasting state to
detect glycaemia, hemoglobin (Hb) and glycated Hb
(HbA1c) which was analyzed by high liquid pressure
chromatography (Menarini Diagnostics, Florence, Italy;
upper normal limit 5.9%). Glomerular filtration rate
(eGFR) was estimated according to the Modification of
Diet in Renal Disease (MDRD) Study method [28].
Plasma level of AD was determined, in duplicate, by
ELISA (Linco Research, Missouri, USA); NT-proBNP
was measured with a chemiluminescent immunoassay
kit (Roche Diagnostic Laboratory, Indianapolis, IN,
USA) on an Elecsys 2010 analyzer. All other biohumoral
parameters are reported in Table 1.
Statistical analysis
Data were analyzed using SPSSW software (version
17) and are presented as mean ± SD or median
(quartiles) - depending on their normal or non-normal
distribution - for continuous variables, and as number
(%) for categorical ones. Categorical and continuous vari-
ables were compared between the two groups of patients
(ND and D) using the Pearson T-test and the chi-square
test, respectively. The difference in AD plasma levels
across the groups was analyzed as follows: first we used
univariate ANOVA model to test the difference among
the three ACC/AHA HF stage subgroups, separately in
the ND and D group; then we compared the level of AD
by coupling the matching stage of ND and D groups. Fi-
nally, BMI, NT-proBNP and HDL cholesterol were intro-
duced in the univariate ANOVA models as covariates;
this choice was supported by the fact that these three
variables have proven to be the strongest predictors of
AD, as previously reported by us [19] and others [3,13].
In the last step, we tested different multivariate backward
stepwise linear regression models with AD as dependentvariable and age, gender, ACC/AHA HF stage, BMI, NT-
proBNP, HDL cholesterol and DM as independent vari-
ables, to test their independent predictive value.Results
Comparison between ND and D groups
The main features of the study population and the main
differences between the two groups (ND and D) are
summarized in Table 1. Briefly, a history of angina and
the presence of atrial fibrillation were slightly more
prevalent among diabetics, although not significant. As
expected glycaemia, HbA1c and BMI were significantly
higher in group D patients, as well as smoking. We also
noticed a worse performance at the 6MWT among dia-
betics which were also more likely to display peripheral
edema despite a better mean LVEF. In accordance to the
literature [29], pericardial fat tissue was thicker in dia-
betics because of their higher BMI. With the exception
of clopidogrel and aldosterone blockers, drugs reported
to be used were similar in the two groups; unexpectedly,
statins were more frequently prescribed in the ND
group. Among diabetics, 14 patients (21.2%) were
treated with diet alone, 14 (21.2%) were prescribed
metformin and 12 (18.2%) a combination of two oral anti-
diabetic drugs. Twenty-six patients (39.4%) were treated
with insulin.Adiponectin
Mean AD level was 9.7±7.3 ng/ml with a signifi-
cantly higher level in the ND compared to the D group
(11.0±8.4 vs 7.9±5.0 ng/ml, p=0.012) (Figure 2A). As
shown in Figure 2B, there was a slight, but not signifi-
cant, increase of AD in group BND compared to AND. A
significant rise was observed in group CND compared to
the other two (p=0.001 and p=0.003, respectively).
Among diabetic subjects (Figure 2C) no difference was
found between AD and BD (6.8±4.2 ng/ml vs 6.3±4.7 ng/ml,
p=0.742), while CD showed a significant increase
(11.0±5.1 ng/ml) compared to both AD (p=0.003) and
BD (p=0.005). We finally matched subjects belonging to
the same clinical stage of HF (A, B, C) but with different
metabolic profile (ND vs. D) (Figure 3): no difference
was found among diabetic and non diabetic patients in
group A (AND 7.4±4.7 ng/ml vs. AD 6.8±4.2 ng/ml,
p=0.722); AD levels became significantly different in
group B (BND 10.7±9.3 ng/ml vs. BD 6.3±4.7 ng/ml,
p=0.042) and even more divergent in group C (CND
15.3±8.8 ng/ml vs. CD 11.0±5.1 ng/ml, p=0.034).
When the analysis of variance of AD in different clin-
ical stages of HF was adjusted for BMI, HDL cholesterol
and NT-proBNP - the main cofactors known to predict
AD plasma levels – the difference in AD still remained
significant in the total population and in the ND group
Table 1 Characteristics of the study population
Variable Total n=150 ND Group n=84 D Group n=66 p value
Age (years) 68.8±10.8 67.6±12.6 70.2±7.6 0.143
Female 13% 14% 12% 0.699
BMI (Kg/m2) 26.7±4 25.2±3.4 28.8±4.2 0.001
History of angina 42% 36% 52% 0.060
Previous ACS 79.6% 82% 79% 0.500
Previous PTCA 75% 73.6% 80.1% 0.307
Previous CABG 27.6% 27.3% 28.8% 0.921
Atrial fibrillation 17.8% 13.1% 24.2% 0.084
Hypertension 69.7% 66.7% 75.8% 0.267
Dyslipidemia 69.7% 70.2% 71.2 0.986
Smoking 63% 51.2% 80% 0.001
COPD 12.5% 11.9% 13.6% 0.773
NYHA class III-IV 19.4% 15.5% 13.6% 0.982
Boston score 2.5±3.4 2.7±3.7 2.2±3.1 0.345
6-min walk test (m) 430.3±170.3 458±180.9 395.8±150.8 0.031
Index Disease Severity (IDS) score 3.7±2.5 2.7±2.1 4.9±2.3 0.345
GDS score 7.4±5.2 7.1±5.2 7.7±5.3 0.493
Third heart sound 5% 7% 3% 0.259
Peripheral edema 16.9% 10% 24% 0.016
Jugular vein distention 11.9% 11.9% 12.1% 0.989
Pericardial fat (mm) 7.9±3.1 7.2±2.8 8.4±3.4 0.041
Myocardial mass 129.6±35.3 130.2±33,9 128.9±37.3 0.835
Ejection fraction (%) 43.9±15 41.3±14.5 47.3±15.6 0.017
Trans-tricuspid gradient (mmHg) 19.9±13.6 21±14 18.5±12.9 0.263
Glycaemia (mg/dl) 118.5±45 94.5±11.9 149.7±52.7 0.001
Hemoglobin (g/dl) 13.6±1.5 13.7±1.5 13.4±1.5 0.202
HbA1c (%) 6.64±1.27 5.9±0.3 7.6±1.4 0.001
eGFR (ml/min) 71.3±25.1 67.8±21.2 75.8±28.8 0.058
Total cholesterol (mg/dl) 170.1±41.8 171.9±39.6 167.9±44.7 0.576
HDL (mg/dl) 43.8±11.5 43.1±10.3 44.8±13 0.363
ESR (mm/h) 33±25.2 36.1±27.4 29.1±21.6 0.101
TSH (mU/l) 2.1±3.7 2.9±4.2 2.2±3 0.786
Albumin (g/dl) 5.1±0.8 3.9±0.4 3.7±0.4 0.147
NT-proBNP (ng/ml) 2101.9±4246.6 2066.8±3243.2 2071.4±5300.1 0.995
ACE/ARB 89.5% 88% 93.9% 0.222
Beta-blockers 82.2% 86.9% 78.8% 0.185
Digitalis 19.7% 19% 21.2% 0.742
Aldosterone blockers 25% 33.3% 15.2% 0.011
Loop diuretics 53.3% 52.4% 56.1% 0.654
Nitrates 29.6% 31% 28.8% 0.774
Statins 78.3% 85.7% 71.2% 0.029
Warfarin 15.1% 15.5% 15.2% 0.956
Aspirin 84.2% 88% 81.8% 0.281
Clopidogrel 40.1% 50% 28.8% 0.009
Abbreviations: BMI, Body Mass Index; ACS, Acute Coronary Syndrome; PTCA, Percutaneous Transluminal Coronary Angioplasty; CABG, Coronary Artery Bypass
Graft; COPD, Chronic Obstructive Pulmonary Disease; GDS, Geriatric Depression Scale; HbA1c, Glycated Hemoglobin; eGFR, estimated Glomerular Filtration Rate;
ESR, Erythrocyte Sedimentation Rate; TSH, Thyroid Stimulating Hormone; ACE/ARB, Angiotensin Converting Enzyme/ACE Receptor Blockers.
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Figure 2 Comparison of adiponectin levels in Non-Diabetic
(ND) vs. Diabetic groups (a), and across different clinical stages
(A, B and C) of HF, separately in ND and D (b and c).
Figure 3 Comparison of adiponectin levels in subjects
belonging to the same clinical stage of HF (A, B and C) but
with different metabolic profile (ND, Non-Diabetics vs. D,
Diabetics).
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after covariate adjustment was not significant.
Independent predictors of AD
In order to elucidate the predictive value of each variable
on AD level we drew different backward stepwise linear
regression models (Table 3). The first model which
included age, gender, ACC/AHA clinical stage of HF and
the presence of diabetes, showed high predictive
strength (R=0.62, p<0.001). In the second model we
added NT-proBNP; as the first one, it showed a good
predictive strength (R=0.63, p<0.001). In the third
and fourth models we introduced BMI first and then
HDL cholesterol; the predictive strength of these models
was still satisfactory (R=0.62, p<0.001; R=0.69, p<0.001
respectively); however, diabetes lost its independent
predictivity.Discussion
It is known that plasma levels of AD are able to predict
diabetes onset and diabetic patients show lower concen-
trations of the adipokine compared to the general popu-
lation [4,6]. Our study extends these observations to a
specific subgroup of DM patients with ischemic chronic
heart failure, exploring the controversial relationship
that exists between AD and HF.Table 2 Analysis of variance of adiponectin plasma levels
across the three subgroups (A, B and C)
Model Unadjusted Adjusted*
F p F p
Total poulation 10.9 <0.001 5.4 0.005
ND group 6.7 0.002 6.1 0.004
D group 6.0 0.004 1.4 0.250
*adjusted for BMI, HDL cholesterol and NT-proBNP.
Abbreviations: ND and D, Non-diabetic and Diabetic group; BMI, Body Mass
Index.
Table 3 Backward stepwise linear regression models
Model 1 Model 2 Model 3 Model 4
R=0.62, <0.001 R=0.63, <0.001 R=0.63, <0.001 R=0.69, <0.001
B±SE p B±SE p B±SE p B±SE p
Age 0.24±0.05 <0.001 0.17±0.05 <0.001 0.10±0.05 0.021 0.07±0.04 0.124
Gender 5.70±1.51 <0.001 4.05±1.49 0.008 4.49±1.41 0.002 1.97±1.47 0.182
ACC/AHA stage 2.47±0.60 <0.001 1.77±0.62 0.005 1.38±0.60 0.023 1.40±0.57 0.016
Diabetes −3.44±0.99 0.001 −2.90±0.95 0.003 −1.37±1.02 0.182 −1.86±0.98 0.061
NT-proBNP 0.01±0.01 0.001 0.01±0.01 <0.001 0.01±0.01 <0.001
BMI −0.30±0.11 0.008 −0.17±0.12 0.164
HDL cholesterol 0.17±0.04 <0.001
Abbreviations: ACC/AHA, American College of Cardiology/American Heart Association; BMI, Body Mass Index.
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increases in patients with CAD and overt HF compared to
those with normal or reduced LVEF but clinically asymp-
tomatic [19]. This is in accordance to the literature which
reports higher AD levels in patients with advanced NYHA
class [13]. We now show that not only clinical staging, but
also a more pathophysiological classification of HF as pro-
posed by ACC/AHA guidelines, is able to predict AD
levels in this subset of patients. NT-proBNP, HDL choles-
terol and age still remain the strongest, independent pre-
dictors of AD [19].
We have shown that AD levels are systematically lower
in diabetics compared to non-diabetics, no matter to what
HF staging class they belong. These data suggest that dia-
betic subjects with reduced LVEF orchestrate a slower rise
of AD which begins only in face of overt HF (group CD).
It is of interest that Chen and coll. in asymptomatic men
with uncomplicated type 2 diabetes found a positive asso-
ciation of circulating AD levels with myocardial glucose
metabolism but not with cardiac function [30].
Because of its cross-sectional nature, our study cannot
elucidate with clarity the pathophysiological mechanisms
that lie under the increase of AD at worsening HF. In any
case, some considerations can arise from the data. First of
all, cardiac cachexia cannot be the main cause of higher
AD levels in HF because none of our study subjects was
underweight and the increase of AD observed between
A/B and C was not coupled to a decrease of BMI. There-
fore, cardiac cachexia is a late process in HF compared to
the increase of AD which seems to be a faster phenomenon.
For the same reason, we cannot offer a definite explan-
ation for the hampered rise of AD that we detected in HF
diabetic subjects. However, we can speculate that diabetics
have lower AD plasma levels to begin with which may
depend from their higher BMI. Indeed, in our backward
stepwise linear regression models, we found that DM loses
its predictivity on AD when BMI was introduced as cofac-
tor. However, if we focus on patients with overt HF (CND
vs. CD) we find that despite a significant difference in AD
levels, BMI was not different (data not shown). These datasuggest that something else, beyond body weight, is able
to modulate adiponectin metabolism in diabetic patients
with HF. A good candidate could be NT-proBNP which
seems to directly induce AD production by adipocytes,
in vitro, and in heart failure patients [17]. Even more
striking, natriuretic peptides are able to increase total and
HMW-adiponectin concentrations in healthy subjects
[31]. It could be assumed that diabetic patients produce
lower levels of NT-proBNP in response of overt HF.
However, this is not the case: in fact the level of NT-
proBNP is not significantly different between diabetics
and non-diabetics belonging to the A and B clinical
stages. Even more, diabetic subjects in the C group have
higher, although not significant, levels of NT-proBNP
when compared to the non-diabetic C subgroup, in spite
of a lower adiponectinemia (data not shown). A question
remains as to what lies between the secretion of NT-
proBNP and the production of AD by adipocytes. Some
sort of “NT-proBNP resistance” may exist in type 2 DM.
Further studies will be required to investigate this hypo-
thesis, comparing the different AD response of diabetic
and non-diabetic subjects to injection of natriuretic peptides.
Finally, Won and coll. found that plasma concentra-
tion of AD was significantly lower in HF patients with
metabolic syndrome compared to HF patients without
metabolic syndrome [32]. In our series, the prevalence
of metabolic syndrome, as defined by ATPIII criteria
[33,34], was 68.2% in diabetic patients and 30.9% in non-
diabetic patients. At multivariate analysis, the presence
of metabolic syndrome was not an independent predictor
of AD plasma levels (data not shown).Study limitations
Our population comprises only ischemic HF and type 2
DM. Heart failure of different etiology (valvular, hyperten-
sive and idiopathic) was not explored. Similarly, we have no
data regarding type 1 DM. Another limitation of the study
is the small number of female subjects (only 13%) that were
included which depended on the nature of the inclusion
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of cross sectional studies also apply to our findings.
Conclusion
We corroborate the finding that AD raises across the
ACC/AHA chronic HF stages but this is less evident in dia-
betic patients. In type 2 DM the progressive increase of AD
in relation to the severity of LV dysfunction is hampered
and becomes evident only in overt HF. The different adipo-
kine profile seems to be partially, but not exclusively, deter-
mined by the well-known predictors of AD. Other
molecular mechanisms, such as a “NT-proBNP resistance”,
acting in diabetic patients, can be hypothesized to explain
the different behavior of this adipokine.
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